Anavex Life Sciences Corp (AVXL)

[williamssc]

I think an important note to Dr Missling et al is that A-273, if approved, the cost would not be shifted to medicare because as a pill it would be covered under ones drug plan. Due to Lecanemab being an infusion plus the associated outpatient costs it was put under medicare billing which set in premium increases for all those on medicare.

And would be smart for the slide to include verbiage on our convenience, safety, and relative tolerability.